相关实验视频
Updated: May 2, 2026
06:17
Measuring the Strength of Mice
Published on: June 2, 2013
57.0K
贝叶斯对以生理学为基础的乙基药业动力学模型在小鼠,大鼠和人类中的药业动力学进行了改进
Y S Lin1, N H Hsieh2, P Schlosser1
1Office of Research and Development, U.S. EPA, Washington, DC 20460, USA.
概括
这项研究开发了一种贝叶斯生理学基础的药理动力学 (PBPK) 模型,用于小鼠,老鼠和人类的乙 (EB). 该模型准确地预测了不同物种的EB和代谢物度,改善了风险评估.
科学领域:
- 毒理学 毒理学 毒理学
- 药理动力学 药理动力学
- 计算生物学 计算生物学
背景情况:
- 基于生理学的药理动力学 (PBPK) 模型对于理解化学动力学至关重要.
- 现有的乙 (EB) PBPK模型缺乏全面的跨物种变异性和不确定性评估.
- 需要一个精细的,基于人口的贝叶斯式PBPK模型来进行 robust EB风险评估.
研究的目的:
- 开发和验证一种基于人群的,贝叶斯式PBPK模型,用于EB吸入动力学.
- 评估EB药理动学的跨物种变异性和不确定性.
- 通过马尔科夫链蒙特卡洛 (MCMC) 方法提高模型参数化和预测准确性.
主要方法:
- 为EB开发了一个基于人口的贝叶斯式PBPK模型.
- 使用马尔科夫链蒙特卡洛 (MCMC) 方法进行参数化.
- 校准和评估模型使用一个全面的数据库在老鼠,老鼠和人类.
主要成果:
- 精细的PBPK模型显示出与现有的EB模型相比更好或相似的匹配.
- EB和代谢物度在物种中一般在3倍误差范围内,除了小鼠脂肪和肺部外.
- 在老鼠和人类中,尿中曼德基酸 (MA) 度的预测很好.
结论:
- 开发的贝叶斯PBPK模型提供了EB药理动力学变异性和不确定性的改进特征.
- 模型预测和实验数据之间的强烈一致性支持其在风险评估中的应用.
- 这种方法有助于从动物研究中推断数据,以告知人类健康评估,促进公共健康.
相关概念视频
01:20Pharmacokinetic Models: Overview
2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
01:21Mechanistic Models: Overview of Compartment Models
587
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
587
01:26Pharmacokinetic Models: Comparison and Selection Criterion
490
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
490
01:27Pharmacodynamic Models: Overview
159
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
159
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
119
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
119
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97